AI Ascent 2026

2026-05-08 · Source: Sequoia Capital · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Emerging Technologies & Innovation, Robotics & Autonomous Systems · Depth: Expert, extended

Summary

AI Ascent IV, hosted by Sequoia on April 20, 2026, in San Francisco, convened over 150 leading AI founders and researchers, including Demis Hassabis, Andrej Karpathy, and Greg Brockman. Sequoia partners highlighted AI as a computational revolution, with Pat Grady advising founders to build "moats," design for "affordance," and exploit the "diffusion" gap. Sonya Huang declared 2026 the "year of agents," while Konstantine Buhler likened AI's impact on cognitive work to the Industrial Revolution's effect on manual labor. The event also featured an interview with DeepMind founder Demis Hassabis, who discussed DeepMind's 2009 inception, its 20-year AGI mission targeting 2030, and the application of AI in science, exemplified by AlphaFold and Isomorphic Labs' drug discovery efforts, and the potential for AI to create new sciences through advanced simulations.

Key takeaway

For AI founders and R&D leaders navigating the current AI landscape, prioritize building defensible customer-centric solutions and designing for intuitive user interaction to bridge the enterprise adoption gap. Your long-term strategy should align with the vision of AI as a fundamental scientific tool, investing in areas like AI for drug discovery and advanced simulations, while maintaining a pragmatic timeline for AGI development, such as the 2030 target.

Key insights

Demis Hassabis envisions AI as the most profound technology, capable of solving intelligence and subsequently all other major scientific and societal challenges.

Principles

• Build "moats" from the customer back.
• Design for "affordance" in AI products.
• Exploit the "diffusion" gap in enterprise AI adoption.

Method

DeepMind's strategy for AGI involved combining deep learning and reinforcement learning, leveraging accelerated computing (GPUs/TPUs), and integrating neuroscience principles.

In practice

• Apply AI to grand scientific challenges like protein folding (AlphaFold).
• Accelerate drug discovery from 10 years to months/weeks using AI (Isomorphic Labs).
• Develop accurate AI-driven simulators for complex systems (Weather Next, virtual cell).

Topics

• AI Ascent
• DeepMind
• Artificial General Intelligence
• AI for Science
• Drug Discovery
• AI Simulations
• AI Entrepreneurship

Best for: AI Scientist, Entrepreneur, Director of AI/ML

Related on AIssential

• Breaking Bottlenecks in Life Sciences R&D with AI Innovation - with Aziz Nazha of Incyte Pharmaceuticals — Effective AI adoption in life sciences hinges on cultural readiness, talent development, robust infrastructure, and realistic expectations.
• 2026 AI Startup Playbook — AI startup success in 2026 demands niche focus, solving real problems, and disciplined execution.
• OpenAI Closes Biggest AI Deal Ever — Current AI research prioritizes exploitation over exploration, hindering fundamental breakthroughs.
• Enterprise AI Adoption at a Moment of Maximum Skepticism - with Nishtha Jain — Unrealistic expectations, misaligned use cases, and neglecting people are key reasons AI pilots fail to scale.
• Martin Shkreli on AI, Pharma, and What Actually Matters — Value capture in AI is shifting from intelligence to economics, necessitating fundamental hardware innovation beyond silicon.
• FYAI: Why startups will help accelerate global AI transformation — The next AI wave prioritizes measurable ROI, deep enterprise integration, and foundational infrastructure over broad experimentation.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Sequoia Capital.